Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,453,184
  • Shares Outstanding, K 2,036,474
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,645 M
  • EBITDA $ 16,656 M
  • 60-Month Beta 0.26
  • Price/Sales 2.56
  • Price/Cash Flow 7.46
  • Price/Book 6.67

Options Overview Details

View History
  • Implied Volatility 29.33% (+0.73%)
  • Historical Volatility 24.83%
  • IV Percentile 37%
  • IV Rank 25.04%
  • IV High 55.70% on 04/10/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 2) 0.90 (1.51%)
  • Put/Call Vol Ratio 1.17
  • Today's Volume 19,792
  • Volume Avg (30-Day) 17,848
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 611,470
  • Open Int (30-Day) 612,216
  • Expected Range 58.94 to 60.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.46
  • Number of Estimates 10
  • High Estimate 1.59
  • Low Estimate 1.39
  • Prior Year 1.80
  • Growth Rate Est. (year over year) -18.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.23 +0.79%
on 02/19/26
62.89 -5.07%
on 03/02/26
-0.23 (-0.38%)
since 02/11/26
3-Month
52.01 +14.79%
on 12/12/25
62.89 -5.07%
on 03/02/26
+8.50 (+16.60%)
since 12/11/25
52-Week
42.52 +40.40%
on 10/29/25
62.89 -5.07%
on 03/02/26
-1.81 (-2.94%)
since 03/11/25

Most Recent Stories

More News
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program

BMY : 59.91 (-0.37%)
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical...

BMY : 59.91 (-0.37%)
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

BMY : 59.91 (-0.37%)
Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the...

BMY : 59.91 (-0.37%)
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

$NASX : 22,648.72 (-0.21%)
LLY : 998.48 (-0.29%)
BMY : 59.91 (-0.37%)
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”) in an interim analysis of a Phase 3 trial (NCT06382142) conducted...

BMY : 59.91 (-0.37%)
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

HELP : 5.43 (-5.40%)
CMPS : 6.98 (-6.18%)
PFE : 27.19 (+0.11%)
TAK : 18.12 (-0.49%)
BMY : 59.91 (-0.37%)
3 Reasons to Avoid BMY and 1 Stock to Buy Instead

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

BMY : 59.91 (-0.37%)
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46 th Annual Health Care Conference on Monday, March 2, 2026. The...

BMY : 59.91 (-0.37%)
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints

BMY : 59.91 (-0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 61.71
2nd Resistance Point 61.33
1st Resistance Point 60.73
Last Price 59.91
1st Support Level 59.76
2nd Support Level 59.38
3rd Support Level 58.78

See More

52-Week High 62.89
Last Price 59.91
Fibonacci 61.8% 55.11
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar